Effect of Pravastatin Therapy on Coronary Events in Carriers of the KIF6 719Arg Allele from the Cholesterol and Recurrent Events Trial

American Journal of Cardiology

Volumn 105, Issue 9, 2010, Pages 1300-1305

  Shiffman, Dov ^a   Sabatine, Marc S ^b   Louie, Judy Z ^a   Kirchgessner, Todd G ^c   Iakoubova, Olga A ^a   Campos, Hannia ^d   Devlin, James J ^a   Sacks, Frank M ^b,d  

^a CELERA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHOLESTEROL; KINESIN FAMILY MEMBER 6; PLACEBO; PRAVASTATIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ETHNIC GROUP; ETHNICITY; FEMALE; GENDER; GENETIC HETEROGENEITY; HAZARD RATIO; HEART INFARCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION STRUCTURE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; THERAPY EFFECT;

ALLELES; ATHEROSCLEROSIS; CHOLESTEROL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINESIN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PRAVASTATIN; PREVALENCE; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 77950864702     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.049     Document Type: Article

References (18)

1. Schmitz G., and Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 44 (2006) 75-89
2. Mangravite L.M., Thorn C.F., and Krauss R.M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 6 (2006) 360-374
3. Iakoubova O.A., Tong C.H., Rowland C.M., Kirchgessner T.G., Young B.A., Arellano A.R., Shiffman D., Sabatine M.S., Campos H., Packard C.J., Pfeffer M.A., White T.J., Braunwald E., Shepherd J., Devlin J.J., and Sacks F.M. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 51 (2008) 435-443
4. Iakoubova O.A., Sabatine M.S., Rowland C.M., Tong C.H., Catanese J.J., Ranade K., Simonsen K.L., Kirchgessner T.G., Cannon C.P., Devlin J.J., and Braunwald E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 51 (2008) 449-455
5. Bare L.A., Morrison A.C., Rowland C.M., Shiffman D., Luke M.M., Iakoubova O.A., Kane J.P., Malloy M.J., Ellis S.G., Pankow J.S., Willerson J.T., Devlin J.J., and Boerwinkle E. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med 9 (2007) 682-689
6. Shiffman D., O'Meara E.S., Bare L.A., Rowland C.M., Louie J.Z., Arellano A.R., Lumley T., Rice K., Iakoubova O., Luke M.M., Young B.A., Malloy M.J., Kane J.P., Ellis S.G., Tracy R.P., Devlin J.J., and Psaty B.M. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 28 (2008) 173-179
7. Shiffman D., Chasman D.I., Zee R.Y., Iakoubova O.A., Louie J.Z., Devlin J.J., and Ridker P.M. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol 51 (2008) 444-448
8. Stewart A.F., Dandona S., Chen L., Assogba O., Belanger M., Ewart G., LaRose R., Doelle H., Williams K., Wells G.A., McPherson R., and Roberts R. Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol 53 (2009) 1471-1472
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
10. Shiffman D., Ellis S.G., Rowland C.M., Malloy M.J., Luke M.M., Iakoubova O.A., Pullinger C.R., Cassano J., Aouizerat B.E., Fenwick R.G., Reitz R.E., Catanese J.J., Leong D.U., Zellner C., Sninsky J.J., Topol E.J., Devlin J.J., and Kane J.P. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 77 (2005) 596-605
11. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., and Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38 (2006) 904-909
12. Iakoubova O.A., Tong C.H., Chokkalingam A.P., Rowland C.M., Kirchgessner T.G., Louie J.Z., Ploughman L.M., Sabatine M.S., Campos H., Catanese J.J., Leong D.U., Young B.A., Lew D., Tsuchihashi Z., Luke M.M., Packard C.J., Zerba K.E., Shaw P.M., Shepherd J., Devlin J.J., and Sacks F.M. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arterioscler Thromb Vasc Biol 26 (2006) 2763-2768
13. Patterson N., Price A.L., and Reich D. Population structure and eigenanalysis. PLoS Genet 2 (2006) e190
14. King J.Y., Ferrara R., Tabibiazar R., Spin J.M., Chen M.M., Kuchinsky A., Vailaya A., Kincaid R., Tsalenko A., Deng D.X., Connolly A., Zhang P., Yang E., Watt C., Yakhini Z., Ben-Dor A., Adler A., Bruhn L., Tsao P., Quertermous T., and Ashley E.A. Pathway analysis of coronary atherosclerosis. Physiol Genomics 23 (2005) 103-118
15. Flack J.M., Victor R., Watson K., Ferdinand K.C., Saunders E., Tarasenko L., Jamieson M.J., Shi H., and Bruschi P. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 83 (2008) 35-45
16. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., and Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
18. Goldberg R.B., Mellies M.J., Sacks F.M., Moye L.A., Howard B.V., Howard W.J., Davis B.R., Cole T.G., Pfeffer M.A., Braunwald E., and The CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 98 (1998) 2513-2519